- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc stock price live, this page displays NASDAQ XENE stock exchange data. View the XENE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xenon Pharmaceuticals Inc real time stock price chart below.
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 62.34.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is "XENE."
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
What Is the Xenon Pharmaceuticals Inc Stock Price Today?
The Xenon Pharmaceuticals Inc stock price today is 62.34.
What Is the Stock Symbol for Xenon Pharmaceuticals Inc?
The stock symbol for Xenon Pharmaceuticals Inc is "XENE."
What Stock Exchange Does Xenon Pharmaceuticals Inc Trade On?
Xenon Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xenon Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xenon Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XENE quote. (ISIN: CA98420N1050)
NASDAQ
Currency in USD
62.34
-1.89(-2.94%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
62.26
63.69
52 wk Range
35.60
72.66
XENE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
62.2663.69
52 wk Range
35.6072.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XENE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
81.30
Upside
+30.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
20 Buy
0 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 81.30
(+30.41% Upside)
Xenon Pharmaceuticals Inc SWOT Analysis
Azetukalner's Promise | Xenon's lead drug candidate shows potential in epilepsy and major depressive disorder, with blockbuster sales projections and upcoming clinical milestones |
Pipeline Progress | Explore Xenon's robust clinical development program, including Phase 3 trials for focal onset seizures and plans for MDD studies |
Market Opportunity | Delve into the substantial market potential for azetukalner, with analysts projecting over $1 billion in sales within 3-5 years post-launch |
Financial Health | Learn about Xenon's strong liquidity position and analyst optimism, with price targets ranging from $55 to $65, despite current unprofitability |
Xenon Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- 10x Genomics beat Q2 2026 EPS estimates at -$1.11 vs. -$1.14 expected; revenue reached $151M including $1.6M Takara settlement payment.
- Full-year 2026 revenue guidance raised to $610M-$630M, implying 2%-5% growth, driven by strong early demand for new Atera spatial platform.
- Consumables revenue grew 7% YoY with spatial up 16%, while instrument sales fell 47% as customers delayed purchases ahead of Atera launch.
- Atera orders exceed 40-unit shipment target, but manufacturing capacity remains limiting factor; Q4 expected to show strong recovery.
- Gross margin improved to 74% from 72% YoY; company holds $552M in cash with minimal debt despite ongoing academic funding headwinds.
Last Updated: 2026-08-06, 06:32 p/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-1.11 / -1.14
Revenue / Forecast
-- / 1.5M
Compare XENE to Peers and Sector
Metrics to compare | XENE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXENEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.7x | −3.7x | −0.4x | |
PEG Ratio | 0.46 | −0.05 | 0.00 | |
Price/Book | 4.9x | 2.5x | 2.6x | |
Price / LTM Sales | - | 39.2x | 3.1x | |
Upside (Analyst Target) | 24.6% | 123.8% | 48.4% | |
Fair Value Upside | Unlock | 12.5% | 6.5% | Unlock |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Xenon Pharmaceuticals (XENE) Stock Price Today?
The Xenon Pharmaceuticals stock price today is 62.34 USD.
What Stock Exchange Does Xenon Pharmaceuticals Trade On?
Xenon Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Xenon Pharmaceuticals?
The stock symbol for Xenon Pharmaceuticals is "XENE."
What Is the Xenon Pharmaceuticals Market Cap?
As of today, Xenon Pharmaceuticals market cap is 6.08B USD.
What Is Xenon Pharmaceuticals's Earnings Per Share (TTM)?
The Xenon Pharmaceuticals EPS (TTM) is -4.73.
When Is the Next Xenon Pharmaceuticals Earnings Date?
Xenon Pharmaceuticals will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is XENE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Xenon Pharmaceuticals Stock Split?
Xenon Pharmaceuticals has split 0 times.
How Many Employees Does Xenon Pharmaceuticals Have?
Xenon Pharmaceuticals has 364 employees.
What is the current trading status of Xenon Pharmaceuticals (XENE)?
As of Aug 14, 2026, Xenon Pharmaceuticals (XENE) is trading at a price of 62.34 USD, with a previous close of 64.23 USD. The stock has fluctuated within a day range of 62.26 USD to 63.69 USD, while its 52-week range spans from 35.60 USD to 72.66 USD.
What Is Xenon Pharmaceuticals (XENE) Price Target According to Analysts?
The average 12-month price target for Xenon Pharmaceuticals is 81.30 USD, with a high estimate of 100 USD and a low estimate of 69 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +30.41% Upside potential.
What Is the XENE Premarket Price?
XENE's last pre-market stock price is 63.51 USD. The pre-market share volume is 670.00, and the stock has decreased by -0.72, or -1.12%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.